Skip to content
Screener

EPS (Diluted) at other companies

Pfizer logo
PfizerPFE
-$0.04-108%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$2.27-0.9%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$12.23-4.5%
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
-$0.81-55.8%
Arvinas logo
ArvinasARVN
-$0.90-179%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
-$1.82+49.7%

Other financials

Income statement

See full
Revenue$65.0M+466%
Operating income-$75.6M+10.6%
Net income-$61.2M+20.1%

Balance sheet

See full
Cash & equivalents$124.5M-62.9%
Total debt$80.1M-8.5%
Total equity$1.5B+55.4%
Total assets$1.6B+45.5%

Cash flow

See full
Operating cash flow-$54.1M+9.7%
CapEx$473.0K-31.9%
Free cash flow-$54.5M+10.0%

Valuation

See full
Market cap$8.68B+199%
Enterprise value$8.63B+225%
P/S82.6×+17.8×

Profitability

See full
Operating margin-333.5%-114pp
Net margin-285.3%-99.7pp
FCF margin-226.6%-84.9pp

Returns & leverage

See full
Return on equity-24.2%-5.2pp
Debt / equity0.1×0.0×
Current ratio10.3×+2.0×

Where this comes from

Reported directly by Kymera Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.

The source filing: Kymera Therapeutics’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 7:15 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333849
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Total other income:14,3967,94329,31816,788
Net loss$(61,211)$(76,614)$(130,445)$(142,195)
Other comprehensive loss:
Unrealized (loss) gain on marketable securities(2,963)337(8,957)1,764
Total comprehensive loss$(64,174)$(76,277)$(139,402)$(140,431)
Net loss$(61,211)$(76,614)$(130,445)$(142,195)
Net loss per share, basic and diluted$(0.62)$(0.95)$(1.33)$(1.77)
Weighted average common stock outstanding, basic and diluted98,177,15880,449,40597,857,48980,298,940

Item 1. Financial Statements.

FAQ

What is Kymera Therapeutics's EPS (diluted)?
Kymera Therapeutics (KYMR) reported EPS (diluted) of -$0.62 in Q2 2026.
How has Kymera Therapeutics's EPS (diluted) changed year-over-year?
Kymera Therapeutics's EPS (diluted) increased by 34.7% year-over-year, from -$0.95 to -$0.62.
What is the long-term trend for Kymera Therapeutics's EPS (diluted)?
Over 4 years (2021 to 2025), Kymera Therapeutics's EPS (diluted) has grown at a 15.5% compound annual growth rate (CAGR), from -$2.07 to -$3.69.
What does EPS (diluted) mean?
Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.

Ask your AI about Kymera Therapeutics's eps (diluted).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude